ORDER Granting Petitioner’s Unopposed Motion to Withdraw and Substitute Counsel 37 C.F.R. § 42.10 | Jun 18, 2026 | PAPER | BOARD |
Patent Owner’s Unopposed Motion to Excuse the Late Filing of Patent Owner’s Exhibits in Support of Its Discretionary Denial Brief | Jun 11, 2026 | PAPER | PATENT OWNER |
Declaration of Andrew V. Trask (June 11, 2026) (“Trask Decl.”) | Jun 11, 2026 | EXHIBIT | PATENT OWNER |
Donald Trump Remarks Transcript, Calls Contracting COVID-19 “Blessing from God” October 7, @Rev, https://www.rev.com/transcripts/donald-trump-remarks-transcript-calls-contracting-covid-19-blessing-from-god-october-7 (last accessed Mar. 19, 2026) (“2020 Transcript”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Kiran Stacey et al., Regeneron: The Company That Trump Claims Cured His Covid, Financial Times (Oct. 9, 2020), https://www.ft.com/content/70672ed3-bf66-4c14-8392-076d0c503558 (“Stacey 2020a”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Kiran Stacey, Trump Calls Coronavirus Treatment He Received a “Cure”, Financial Times (Oct. 7, 2020), https://www.ft.com/ content/a792326c-40e7-460d-ac38-8a9b03286ea0 (“Stacey 2020b”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Rahul N. Khurana et al., Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration, 128 Ophthalmology 1027 (2021) (“Khurana 2021”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Public Trial Transcript Excerpts, Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 22-cv-61 (N.D.W. Va.) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
AbbVie, Allergan, an AbbVie Company, and Molecular Partners Receive Complete Response Letter from FDA on Biologics License Application for Abicipar Pegol, AbbVie News Center (June 26, 2020), https://news.abbvie.com/2020-06-26-Allergan-an-AbbVie-Company-and-Molecular-Partners-Receive-Complete-Response-Letter-from-FDA-on-Biologics-License-Application-for-Abicipar-pegol (“AbbVie Press Release”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Beovu Label (2024) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Novartis, Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program, Novartis Media Releases (May | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Philip J. Rosenfeld & David J. Browning, Editorial: Is This a 737 Max Moment for Brolucizumab?, 216 Am. J. Ophthalmology A7 (2020) (“Rosenfeld”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Eylea HD® Highlights of Prescribing Information (Oct. 2024) (“Eylea HD® Label) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
John S.Y. Park & David R. Chow, Clinical Primer on Eylea HD: Review of the Current Data, Retina Specialist (Apr. 13, 2024), https://www.retina-specialist.com/article/clinical-primer-on-eylea-hd-review-of-the-current-data (“Park”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
U.S. Food & Drug Admin., Eylea HD® Approval Letter (August 18, 2023) (“Eylea HD® FDA Approval Letter”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Declaration of Daniel Van Plew (June 8, 2026) (“Van Plew Decl.”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Berkeley Lovelace Jr., FDA Approves First Gene Therapy for Genetic Hearing Loss, NBC News (Apr. 23, 2026), https://www.nbcnews.com/health/health-news/fda-approves-first-gene-therapy-genetic-hearing-loss-rcna341666 (“Lovelace”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Manufacturing Operations: Overview, Biocon, https://www.biocon.com/businesses/generics/overview-manufacturing-operations/ (last accessed May 27, 2026) (“Biocon Manufacturing”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Regeneron, Release Details: Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. (Apr. 23, 2026), https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only (“Otarmeni Release”) | Jun 9, 2026 | EXHIBIT | PATENT OWNER |
Petitioners' Unopposed Motion to Withdraw and Substitute Counsel | Jun 9, 2026 | PAPER | PETITIONER |
Petitioners' Updated Power of Attorney | Jun 9, 2026 | PAPER | PETITIONER |
Petitioners' Updated Mandatory Notices | Jun 9, 2026 | PAPER | PETITIONER |
Patent Owner's Discretionary Denial Brief | Jun 8, 2026 | PAPER | PATENT OWNER |
E-mail authorizing motion to withdraw | Jun 5, 2026 | EXHIBIT | BOARD |
Petitioner's Reply to Patent Owner's Opposition to Petitioner's Motion for Joinder | May 29, 2026 | PAPER | PETITIONER |
Patent Owner's Opposition to Petitioner's Joinder Motion | Apr 30, 2026 | PAPER | PATENT OWNER |
Notice: Mandatory Notice | Apr 22, 2026 | PAPER | PATENT OWNER |
Notice: Power of Attorney | Apr 22, 2026 | PAPER | PATENT OWNER |
Notice: Notice filing date accorded | Apr 7, 2026 | PAPER | BOARD |
EX.1001 - U.S. Patent 12,168,036 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 1 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 2 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 3 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 4 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 5 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 6 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1002 - U.S. Patent 12,168,036 File History Part 7 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1003 - Declaration of Dr. Donald Joseph D’Amico | Apr 2, 2026 | EXHIBIT | PETITIONER |
Ex.1004 - Declaration of Dr. Robert J. Falconer | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1005 - U.S. Patent 7,608,261 (Furfine) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1006 - U.S. Patent 8,921,316 (Dix) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1007 - U.S. Pub. 2016/0144025 (Vitti) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1008 - 2011 Eylea® Clinical Review | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1009 - AU Eylea® Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1010 - U.S. Pub. 2015/0071920 (Larson) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1011 - U.S. Publication 2017/0232199 (Fiedler) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.2012 WO 2016/154288 (Ingber) | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1013 - U.S. 7,374,758 PTE Application | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1014 - Avery 2014 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1015 - Awwad 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1016 - Brown 2015 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1017 The CATT Research Group 2011 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1018 - Celik 2015 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1019 - Cohen and Gardner | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1020 - Das 2015 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1021 - Dear 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1022 - Duh 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1023 - Elwes 2018 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1024 - Falavarjani and Nguyen | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1025 - He 2011 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1026 - Ho 2014 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1027 - Hong 2018 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1028 - Inoue 2014 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1029 - Jin and Hwang | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1030 - Presentation for Lehman Brothers Healthcare Conference | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1031 - Miller 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1032 - Narasimhan 2012 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1033 - Neergaard 2013 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1034 - Nguyen 2009 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1035 - Nguyen 2012 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1037 - Gutierrez and Ferrara | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1038 - Salinas 2010 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1039 - Stewart 2012 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1040 - Sun 2012 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1041 - Trichonas and Kaiser | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1042 - Varma 2014 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1043 - Viswanath 2007 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1044 - Wang 2015 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1045 - Wang 2021 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1047 - Wykoff 2018 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1048 - Macugen 2011 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1049 - Beovu 2019 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1050 - Eylea 2011 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1051 - Eylea 2012 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1052 - Eylea 2014 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1053 - Eylea 2016 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1054 - Eylea HD 2024 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1055 - Lucentis 2017 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1057 - Vabysmo 2022 Label | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1058 - EMA Report | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1059 - Eylea Pharmacology Review | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1060 - EMA Annex | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1061 - Loureiro 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1062 - Ferrara 2010 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1063 - Channa 2011 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1064 - Rhoades 2017 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1065 - Declaration of June Ann Munford | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1066 - Clinical Study Protocol NCT04126317 | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1067 - Declaration of Dr. Jay Stewart, M.D. | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX.1068 - Declaration of Dr. Barrett Rabinow, M.D. | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX1069 - Alvotech Petition | Apr 2, 2026 | EXHIBIT | PETITIONER |
EX1070 - Alvotech Institution Decision | Apr 2, 2026 | EXHIBIT | PETITIONER |
Petition: as filed | Apr 2, 2026 | PAPER | PETITIONER |
Notice: Power of Attorney | Apr 2, 2026 | PAPER | PETITIONER |
Motion: Joinder | Apr 2, 2026 | PAPER | PETITIONER |